War and peace? The oncologic and the palliative care perspective on personalized cancer treatment in a patient with advanced cancer

被引：0
作者：
Eva K. Masel
Sophie Schur
Doris Posch
Dietmar Weixler
Johannes G. Meran
Manuela Schmidinger
Herbert H. Watzke
机构：
[1] Medical University of Vienna,Clinical Division of Palliative Care, Department of Internal Medicine I
[2] Medical University of Vienna,Clinical Division of Oncology, Department of Internal Medicine I
[3] Hospital Barmherzige Brueder,Department of Internal Medicine, Haematology and Oncology
[4] Hospital Horn-Allentsteig,Palliative Care Consult Team
来源：
Wiener klinische Wochenschrift | 2015年 / 127卷
关键词：
Medical oncology; Molecular targeted therapy; Neoplasms; Palliative care; Terminal care;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Personalized cancer treatment utilizing targeted therapies in a tailored approach is based on tumor and/or patient-specific molecular profiles. Recent clinical trials continue to look for new potential targets in heavily pretreated patients or rare disease entities. Careful selection of patients who may derive benefit from such therapies constitutes a challenge. This case report presents an experimental personalized cancer treatment in an advanced cancer patient and provides a list of issues for discussion: How can we combine treatment goals and simultaneously meet the individual needs in advanced cancer reconciling both perspectives: oncology and palliative care?
引用
收藏
页码：635 / 638
页数：3
相关论文
共 57 条
  • [1] Ng PC(2009)An agenda for personalized medicine Nature 461 724-6
  • [2] Murray SS(2013)Modified FOLFOX6 chemotherapy in patients with metastatic urachal cancer Chemotherapy 59 402-6
  • [3] Levy S(2014)Unintended consequences of expensive cancer therapeutics-the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture JAMA Otolaryngol Head Neck Surg 28 1225-36
  • [4] Venter JC(1999)Diagnosing suffering: a perspective Ann Intern Med 131 531-4
  • [5] Yanagihara Y(2014)Expected survival with and without second-line palliative chemotherapy: who wants to know? Health Expect 10 12275-2
  • [6] Tanji N(2014)Extending life or prolonging death: when is enough actually too much? J Vasc Surg 60 521-25
  • [7] Miura N(2012)Patients’ expectations about effects of chemotherapy for advanced cancer N Engl J Med 367 1616-4
  • [8] Shirato A(1987)The philosophy of terminal cancer care Ann Acad Med Singapore 16 151-7
  • [9] Nishimura K(2013)Best care for the dying patient BMJ 347 f4428-40
  • [10] Fukumoto T(2010)Invasive palliative interventions: when are they worth it and when are they not? Cancer J 16 483-11
123456